A Phase 4 interventional study of Alphintern® , tablet, Amoun, Egypt in Mandibular Abscess, sponsored by Ain Shams University. Not yet recruiting at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2023-12-11.
Sponsored by Ain Shams University · Phase 4, Interventional, and Treatment
assessment of healing potentiality of peri apical lesions using different doses of trypsin and alpha chemo trypsin in mandibular molars with chronic apical abscess
Owing to anti-inflammatory, anti-oedematous, fibrinolytic, anti-infective, and analgesic effects, trypsin:
chymotrypsin oral combination has emerged as a promising treatment of mandibular molars with chronic apical abscess. Trypsin chymotrypsin combination always showed a significant reduction in swelling and pain postoperatively.
Study procedures:
152 studies on the registry are indexed under Abscess; 22 are open to participants now.
This study's planned enrollment of 45 is below the median of 110 across 120 interventional studies indexed under Abscess.
Browse Abscess studies →Ain Shams University is the lead sponsor of 1,950 studies on the registry; 429 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group A will receive (Alphintern® tablet, Amoun, Egypt),
Drug: Alphintern® , tablet, Amoun, Egypt
Group B will receive (Limitless Allzyme Max®, tablet, Eva, Egypt)
Drug: Alphintern® , tablet, Amoun, Egypt
Group C will not receive medication
Medications will be taken three times daily for 7 days postoperative, after that all cases will be reexamined regarding healing rate, adverse effect and failure rate of medical treatment.
Also known as: Limitless Allzyme Max®, tablet, Eva, Egypt
Lesion size and bone Formation will be measured by cone-beam computed tomography
cone-beam computed tomography will be done Before Drug is given and after 6 months
Time frame: 6 months
Plan to share: No
This study is not yet recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.